Horng Chen
The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies function using drugs Sacubatril/Valsartan (Entresto) and MANP.
Visit 1 Consent Visit: Possible study participants will meet with study coordinator to review consent form. After enrollment into the study. Diet instructions will be given by a dietician about a no added salt diet, 120 mEq Na/day, which will be maintained throughout the study period. Comprehensive metabolic panel and complete blood count with differential and uring pregnancy test (for premenopausal women) will be obtained as well as a brief physical exam or nursing assessment. Visit 2 will be scheduled at least one week out from consent visit to accommodate diet compliance, unless participan…
Inclusion Criteria: Group 1: HFpEF-CKD-will consist of 30 subjects with: * Ejection fraction of equal or greater than 55%; and * Evidence of increased LV filling pressures, including at least 2 of the following: average septal-lateral E/e' ratio ≥ 15; tricuspid regurgitation (TR) peak velocity \> 2:8 m/s; * Left atrial volume index \>34mL/m\^2 assessed by echocardiography; and * Previous diagnosis of HF with New York Heart Association (NYHA) functional class II-III symptoms on chronic diuretic therapy; and * CKD defined as glomerular filtration rate (eGFR) of 15-80 mL/min/1.73 m\^2 as estima…
Single subcutaneous injection 5 µg/Kg
Oral single dose 97/103 mg
Oral single dose that contains no active ingredient
Single subcutaneous injection that contains no active ingredient
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.